These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2414358)

  • 21. Human lymphoblastoid interferon therapy in chronic hepatitis B virus carriers.
    Alexander GJ
    Chemioterapia; 1988 Dec; 7 Suppl 3():9-11. PubMed ID: 3248319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long term follow up of chronic hepatitis B virus infection in intravenous drug abusers and homosexual men.
    Moestrup T; Hansson BG; Widell A; Nordenfelt E; Hägerstrand I
    Br Med J (Clin Res Ed); 1986 Mar; 292(6524):854-7. PubMed ID: 3083909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral treatment of chronic type B hepatitis.
    Hoofnagle JH
    Ann Intern Med; 1987 Sep; 107(3):414-5. PubMed ID: 2441635
    [No Abstract]   [Full Text] [Related]  

  • 24. Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis.
    Hoofnagle JH; Hanson RG; Minuk GY; Pappas SC; Schafer DF; Dusheiko GM; Straus SE; Popper H; Jones EA
    Gastroenterology; 1984 Jan; 86(1):150-7. PubMed ID: 6196251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphoblastoid interferon therapy of chronic HBV infection. A comparison of 12 vs. 24 weeks of thrice weekly treatment.
    Scully LJ; Shein R; Karayiannis P; McDonald JA; Thomas HC
    J Hepatol; 1987 Aug; 5(1):51-8. PubMed ID: 3655310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection.
    Weller IV; Lok AS; Mindel A; Karayiannis P; Galpin S; Monjardino J; Sherlock S; Thomas HC
    Gut; 1985 Jul; 26(7):745-51. PubMed ID: 2410328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of interferon on hepatitis B virus infection in patients with chronic active hepatitis].
    Hinoue Y; Unoura M; Kato Y; Kobayashi K; Hattori N
    Gan To Kagaku Ryoho; 1984 Feb; 11(2):205-11. PubMed ID: 6696458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection.
    Brook MG; Chan G; Yap I; Karayiannis P; Lever AM; Jacyna M; Main J; Thomas HC
    BMJ; 1989 Sep; 299(6700):652-6. PubMed ID: 2508850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HBsAg-positive chronic liver disease: inhibition of DNA polymerase activity by vidarabine.
    Chadwick RG; Bassendine MF; Crawford EM; Thomas HC; Sherlock S
    Br Med J; 1978 Aug; 2(6136):531-3. PubMed ID: 698557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell-mediated immune response to liver tissue antigen and hepatitis B surface antigen after infection with hepatitis B virus in humans.
    Tiku ML; Beutner KR; Tiku K; Ogra PL
    J Infect Dis; 1978 Nov; 138(5):587-96. PubMed ID: 712116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of chronic hepatitis B (HBeAg-HBV DNA-positive) with lymphoblastoid alpha interferon with or without corticosteroids: short- and long-term follow-up.
    Zavaglia C; Bottelli R; Bellati G; Asti L; Mondazzi L; Iamoni G; Zanetti A; Tanzi E; Fesce E; Gelosa F; Maggi G; Ideo G
    Ital J Gastroenterol; 1996; 28(6):324-31. PubMed ID: 8891847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell-mediated immunity to hepatitis B surface antigen in blood donors with persistent antigenaemia.
    Lee WM; Reed WD; Mitchell CG; Woolf IL; Dymock IW; Eddleston AL; Williams R
    Gut; 1975 Jun; 16(6):416-20. PubMed ID: 1080125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells.
    Akbar SM; Abe M; Masumoto T; Horiike N; Onji M
    J Hepatol; 1999 May; 30(5):755-64. PubMed ID: 10365798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B antigens and antibodies in asymptomatic carriers and in chronic liver diseases.
    Nakamura S; Takezawa Y; Sato T; Maeda T; Nakamura M; Kera K
    Tohoku J Exp Med; 1979 May; 128(1):81-7. PubMed ID: 452007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sex difference in chronic hepatitis B virus infection: studies of serum HBeAg and alanine aminotransferase levels in 10,431 asymptomatic Chinese HBsAg carriers.
    Chu CM; Sheen IS; Lin SM; Liaw YF
    Clin Infect Dis; 1993 May; 16(5):709-13. PubMed ID: 8507764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spontaneous loss of HBeAg and the prevalence of HTLV-III/LAV infection in a cohort of homosexual hepatitis B virus carriers and the implications for antiviral therapy.
    Weller IV; Brown A; Morgan B; Hawkins A; Briggs M; Waite J; Cameron CH; Tedder R
    J Hepatol; 1986; 3 Suppl 2():S9-16. PubMed ID: 3298414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modification of hepatitis B virus infection by recombinant leukocyte alpha A interferon.
    Hess G; Meyer zum Büschenfelde KH
    Immunobiology; 1986 Sep; 172(3-5):255-61. PubMed ID: 3643162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial.
    Perrillo RP; Regenstein FG; Peters MG; DeSchryver-Kecskemeti K; Bodicky CJ; Campbell CR; Kuhns MC
    Ann Intern Med; 1988 Jul; 109(2):95-100. PubMed ID: 3289433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. e System and intrahepatocelullar HBcAG and HBsAG in HBsAG positive patients with liver diseases and healthy carriers.
    Hess G; Nielsen JO; Arnold W; Büschenfelde KH
    Scand J Gastroenterol; 1977; 12(3):325-30. PubMed ID: 866995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.